Evidence map›Paper›PMID 31865445›Full record

ReviewRheumatology international2020

Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.

Enrique Esteve-Valverde, Alfonso Tapiz-Reula, Domingo Ruiz, Jaume Alijotas-Reig

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Drug-associated porphyria: a pharmacovigilance study.Orphanet journal of rare diseases · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Enrique Esteve-ValverdeDepartment of Internal Medicine, Sant Joan de Deu Hospital, Althaia Healthcare University Network of Manresa, Catalonia, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1403-8419
Alfonso Tapiz-ReulaDepartment of Internal Medicine, Sant Joan de Deu Hospital, Althaia Healthcare University Network of Manresa, Catalonia, Barcelona, Spain.
Domingo RuizDepartment of Internal Medicine, Sant Joan de Deu Hospital, Althaia Healthcare University Network of Manresa, Catalonia, Barcelona, Spain.
Jaume Alijotas-ReigDepartment of Medicine, Universitat Autonòma, Catalonia, Barcelona, Spain. jalijotas@vhebron.net.ORCID http://orcid.org/0000-0002-9212-3619
Althaia · ESHebron University · PSUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Porphyrias, particularly acute intermittent porphyria (AIP), are rare disorders which could be associated with systemic lupus erythematosus (SLE). Although the association with AIP has been known since 1952, only 11 cases have been published to date. It is widely known that precipitating causes such as infections, hormonal changes, sunlight exposure, stress and drugs could provoke an AIP crisis. Hydroxychloroquine (HCQ) is usually used in lupus patients, but rarely appears to trigger AIP crises even in SLE patients. The case of a 51-year-old man in whom AIP onset was probably due to hydroxychloroquine use during SLE management is presented. SLE onset was accompanied by fever, pleural, lung and joint involvement with a characteristic SLE autoantibody panel. Although prednisone was given, the joint symptoms did not subside. HCQ was then started; however, some days later the patient suffered anxiety, vomiting and severe abdominal pain refractory to pain-relief drugs and liver function had worsened. No cutaneous lesions were observed. The patient suffered similar episodes accompanied by paralytic ileus and dark-coloured urine, the sediment of which showed no abnormalities. In addition, no myoglobinuria was found. This finding raised the suspicion of AIP and urine tests revealed elevated values of delta-aminolevulinic acid and porphobilinogen. Hydroxychloroquine was preventively suspended and the patient improved notably within a few days. In the following months, the patient suffered no relapse and the prednisone dose could be lowered. Finally, a review of the literature on this topic highlighted the exceptional nature of an API/ SLE association particularly in men. Interestingly, porphyria may present first followed by SLE, or vice versa. The latency period between drug administration and disease onset varies from days to 2 years. Both chloroquine and HCQ may induce PAI in SLE patients. Clinicians should be alerted to a possible association with AIP when a patient with SLE recently put on HCQ presents acute onset of abdominal and/or neurological symptoms and dark urine. Appropriate tests and prompt HCQ cessation are mandatory.

Indexed as

Antirheumatic AgentsHumansHydroxychloroquineLupus Erythematosus, SystemicMaleMiddle AgedPorphyria, Acute IntermittentAntirheumatic AgentsHydroxychloroquineAcute intermittent porphyriaAntimalarialsHydroxychloroquinePorphyria crisisSystemic lupus erythematosusTreatment

Identifiers

PMID31865445
OpenAlexW2995591204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.